Response to anti-HCV therapy in HIV-HCV-coinfected patients: does the lipid profile really have an effect?

Date publication

janvier 2010

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PETIT Jean-Michel

Tous les auteurs :
Petit JM, Carrat F, Duong M, Halfon P, Duvillard L, Bani-Sadr F, Chavanet P, Cacoub P, Piroth L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/20710062

Résumé

BACKGROUND: Because high serum low-density lipoprotein (LDL) and total cholesterol concentrations before treatment have been found to be significant positive prognostic factors for a sustained virological response to HCV therapy in monoinfected patients, the aim of this study was to assess this relationship in HIV-HCV-coinfected patients. METHODS: Pretreatment fasting lipid parameters (in particular total cholesterol, LDL, high-density lipoprotein [HDL], apolipoprotein B [apoB] and triglycerides [TG]) were assessed in 315 patients from the French National Agency for Research on AIDS and Viral Hepatitis (ANRS) HC02-Ribavic therapeutic trial. RESULTS: There was a significant correlation between pretreatment lipid parameters and steatosis (total cholesterol r=-0.23, P

Référence

Antivir Ther. 2010;15(5):797-800.